Skip to main content
Premium Trial:

Request an Annual Quote

Acclerys Stock Climbs 6 Percent After Analyst Begins Coverage, Lauds Firm s Clean Balance Sheet

NEW YORK, March 14 (GenomeWeb News) - Shares in Accelrys were up 6 percent, or $.30, at $5.30 in mid-afternoon trading after a securities analyst began covering the company today and gave the stock a 'Buy' rating.


"We believe Accelrys is a sound nanotechnology play," Braswell said in a statement today. "With $59.1 million in gross cash and no long-term debt, Accelrys has arguably the cleanest balance sheet among our coverage universe of companies in the nanotech space.


"The company also has a large, stable base of blue chip customers in the pharmaceutical and materials industries," Braswell added.


J. Andrew Braswell, an analyst with Newbridge Securities, said he expects the stock to reach $9 in 12 months. He said that shares in Accelrys are "currently undervalued, in our opinion."

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.